BTB/POZ domain-containing protein 14B (BTBD14B) is a protein that in humans is encoded by the BTBD14B gene. The protein is characterized by the presence of a BTB/POZ domain, a protein-protein interaction motif that allows it to participate in diverse cellular functions.BTBD14B, like other proteins containing the BTB/POZ domain, is thought to be involved in protein-protein interactions and may play a role in the regulation of cellular processes such as transcription, cytoskeleton dynamics, ion channel assembly and gating, and protein degradation.
However, other proteins in the BTB/POZ domain-containing family have been implicated in various biological processes and diseases, including cancer and neurodegenerative disorders, suggesting that BTBD14B could also play important roles in human health and disease.For instance, some BTB/POZ domain-containing proteins are known to act as transcriptional regulators, influencing gene expression by interacting with other proteins to modulate the activity of transcription factors. Continuing research into BTBD14B and other BTB/POZ domain-containing proteins will likely provide valuable insights into their roles in cellular function and their implications for human health and disease.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor which may affect protein degradation pathways potentially linked with BTBD14B. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is another proteasome inhibitor that can impact protein turnover and possibly influence BTBD14B functions. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome, affecting protein degradation pathways that could be relevant to BTBD14B. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, potentially affecting protein folding and stability, possibly influencing BTBD14B. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium homeostasis in the endoplasmic reticulum, potentially impacting cellular processes involving BTBD14B. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits protein synthesis, potentially altering the cellular context in which BTBD14B functions. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin, another HSP90 inhibitor, could influence protein folding and degradation pathways involving BTBD14B. | ||||||